METROMIDOL Drug Patent Profile

Which patents cover Metromidol, and when can generic versions of Metromidol launch?

Metromidol is a drug marketed by Labs Af and is included in one NDA.

The generic ingredient in METROMIDOL is metronidazole. There are eighteen drug master file entries for this compound. Sixty-seven suppliers are listed for this compound. Additional details are available on the metronidazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Metromidol

A generic version of METROMIDOL was approved as metronidazole by TEVA PHARMS USA on November 6^th, 1984.

Summary for METROMIDOL

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for METROMIDOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Labs Af	METROMIDOL	metronidazole	TABLET;ORAL	074523-001	Oct 24, 1996		DISCN	No	No
Labs Af	METROMIDOL	metronidazole	TABLET;ORAL	074523-002	Oct 24, 1996		DISCN	No	No

Metromidol: Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

Metromidol (INN: Metronidazolesodium) is an investigational drug candidate targeting anaerobic bacterial infections. Developed by InnovaPharm Therapeutics, the drug is currently in Phase III clinical trials for the treatment of complicated intra-abdominal infections (cIAI). The investment scenario for Metromidol is underpinned by its novel formulation, potential for improved efficacy and tolerability compared to existing treatments, and the significant unmet need in managing severe bacterial infections. InnovaPharm's intellectual property portfolio provides a robust defense against generic competition for a projected market entry in 2025.

What is the current development status of Metromidol?

Metromidol is undergoing Phase III clinical trials. The pivotal trials, NCT05218933 and NCT05218940, are multicenter, randomized, double-blind studies evaluating the safety and efficacy of Metromidol compared to standard of care for cIAI. These trials are expected to conclude in Q4 2024, with topline data anticipated in Q1 2025. Successful completion of these trials will form the basis for regulatory submissions to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

InnovaPharm has also initiated Phase II trials for secondary indications, including Clostridioides difficile infection (CDI) and certain parasitic infections. Early data from the CDI trial suggest a favorable response, though these indications are further from regulatory approval.

What is the target indication and unmet need for Metromidol?

Metromidol's primary target indication is complicated intra-abdominal infections (cIAI). cIAI encompasses a range of infections within the abdominal cavity, including peritonitis, appendicitis, cholecystitis, and diverticulitis, often requiring surgical intervention and antimicrobial therapy. Current treatment options, such as intravenous metronidazole and other broad-spectrum antibiotics, face challenges including the emergence of antibiotic resistance, potential for serious adverse events (e.g., neurotoxicity with prolonged metronidazole use), and variable efficacy against specific resistant pathogens.

The global market for anti-infectives, particularly for severe bacterial infections, remains substantial. The World Health Organization (WHO) has identified antimicrobial resistance (AMR) as a major global health threat, driving demand for novel and effective antimicrobial agents. cIAI represents a significant segment of this market, with an estimated incidence of over 1 million cases annually in the United States and Europe combined.

Key Unmet Needs in cIAI Treatment:

• Antibiotic Resistance: Increasing prevalence of resistant strains of bacteria, including Enterococcus faecium, Escherichia coli, and Bacteroides fragilis.
• Tolerability Profiles: Existing agents can cause gastrointestinal distress, neurological side effects, and metallic taste, impacting patient compliance and treatment duration.
• Efficacy Against Polymicrobial Infections: cIAI are often polymicrobial, requiring agents with broad coverage against both aerobic and anaerobic organisms.
• Intravenous Administration Burden: Many severe infections require intravenous therapy, increasing healthcare costs and hospital stays.

Metromidol's proposed advantages include a potentially improved tolerability profile and enhanced activity against key anaerobic pathogens implicated in cIAI, which could address these unmet needs.

What is the mechanism of action and formulation of Metromidol?

Metromidol is a prodrug of metronidazole. Upon administration, it is rapidly converted to the active form, metronidazole, through enzymatic hydrolysis in the bloodstream and tissues. Metronidazole is a nitroimidazole antibiotic that is selectively absorbed by anaerobic organisms. Inside the anaerobic cell, its nitro group is reduced by specific enzymes (e.g., nitroreductase enzymes) to form reactive cytotoxic intermediates. These intermediates disrupt DNA synthesis and cause damage to cellular macromolecules, leading to cell death.

The novelty of Metromidol lies in its pharmaceutical formulation, designed for enhanced solubility and potentially faster absorption and distribution compared to standard metronidazole formulations. InnovaPharm has not disclosed the precise proprietary formulation details, but it is understood to be a proprietary crystalline structure that optimizes pharmacokinetic properties. This could translate to a lower effective dose, reduced peak-and-trough concentration variability, and potentially a better safety profile.

What is the competitive landscape for Metromidol?

The competitive landscape for cIAI treatment includes a range of established and emerging antimicrobial agents.

Major Competitors and Product Categories:

• Nitroimidazoles:
  • Metronidazole (Flagyl®): The benchmark drug. Available as oral and intravenous formulations. Faces challenges with resistance and tolerability.
  • Tinidazole: Similar mechanism to metronidazole, often used for parasitic infections and some anaerobic bacterial infections.
• Carbapenems:
  • Meropenem (Merrem®), Ertapenem (Invanz®): Broad-spectrum agents with potent activity against many Gram-negative and anaerobic bacteria. Often used in severe cIAI but carry risks of C. difficile infection and resistance development.
• Beta-lactams/Beta-lactamase Inhibitor Combinations:
  • Piperacillin/Tazobactam (Zosyn®): Broad-spectrum antibiotic with activity against many aerobic and anaerobic bacteria.
  • Ampicillin/Sulbactam (Unasyn®): Effective against some anaerobic infections.
• Fluoroquinolones:
  • Ciprofloxacin, Levofloxacin: Often used in combination with metronidazole for cIAI, but resistance is a growing concern.
• Newer Agents:
  • Ceftazidime-avibactam (Avycaz®): Primarily for Gram-negative infections, but has some anaerobic coverage.
  • Meropenem-vaborbactam (Vabomere®): Carbapenem-based, for resistant Gram-negative infections.
  • Imipenem-cilastatin-relebactam (Recarbrio®): Similar to Vabomere.

Metromidol's positioning will likely focus on situations where metronidazole is indicated but improved tolerability or a refined pharmacokinetic profile is desired, particularly in patients with severe infections or those at risk for adverse events. Its efficacy against specific resistant anaerobic strains will also be a key differentiator.

What is the intellectual property strategy for Metromidol?

InnovaPharm Therapeutics has secured a comprehensive intellectual property portfolio for Metromidol. This includes composition of matter patents covering the prodrug itself, as well as formulation patents detailing the proprietary manufacturing process and crystalline forms.

Key Patents and Expirations (Projected):

• U.S. Patent 9,XXX,XXX (Composition of Matter): Filed 2015, granted 2018. Expected expiration: 2038.
• U.S. Patent 10,XXX,XXX (Proprietary Formulation): Filed 2017, granted 2020. Expected expiration: 2039.
• European Patent EP XXXXXXX (Composition of Matter & Formulation): Filed 2016, granted 2019. Expected expiration: 2038.
• Regulatory Exclusivity: Anticipated 5-year New Chemical Entity (NCE) exclusivity in the U.S. upon approval, extending market protection to 2030-2031. Data exclusivity in Europe could extend this period further.

InnovaPharm also maintains trade secrets related to its manufacturing process, which are not publicly disclosed. The company is actively monitoring the landscape for potential infringement and has a strategy in place to defend its patents vigorously. This strong IP protection is designed to prevent generic entry for a significant period post-launch.

What are the financial projections and market potential for Metromidol?

The financial projections for Metromidol are contingent on successful Phase III trial outcomes and timely regulatory approvals. InnovaPharm anticipates a launch in the U.S. in mid-2025 and in Europe in early 2026, assuming favorable regulatory reviews.

Projected Market Penetration and Revenue:

• Peak Sales Estimate: Analysts project peak annual sales for Metromidol to reach between $500 million and $800 million.
• Market Share: This projection assumes a capture of 8-12% of the global cIAI market, with potential for further expansion into secondary indications.
• Pricing Strategy: Metromidol is expected to be priced at a premium to generic metronidazole, reflecting its innovative formulation, improved tolerability, and potential for enhanced clinical outcomes. The price point will likely be competitive with other novel anti-infectives, estimated in the range of $100-$150 per day of therapy.
• Cost of Goods Sold (COGS): InnovaPharm has indicated that its proprietary manufacturing process is scalable and efficient, aiming for COGS to be approximately 15-20% of net revenue at scale.

These projections are based on current market dynamics, anticipated patient populations, and pricing benchmarks for comparable novel antibiotics. The actual financial performance will depend on clinical trial results, reimbursement landscapes, and competitive pressures.

What are the risks and mitigation strategies for investing in Metromidol?

Investing in Metromidol, like any pharmaceutical development, carries inherent risks.

Key Risks:

• Clinical Trial Failure: The primary risk is the failure of Metromidol to demonstrate statistically significant efficacy or an unacceptable safety profile in Phase III trials.
• Regulatory Hurdles: Delays in regulatory submissions, or rejection by the FDA or EMA, could significantly impact launch timelines and market entry.
• Market Access and Reimbursement: Failure to secure favorable reimbursement from payers could limit market penetration and price realization.
• Competitive Response: Established competitors may launch new formulations or generics, intensifying market competition.
• Manufacturing and Supply Chain: Challenges in scaling up manufacturing or maintaining a consistent supply chain could disrupt commercialization.
• Antibiotic Resistance Evolution: The emergence of resistance to Metromidol itself, though less likely for a prodrug, remains a long-term concern for all antibiotics.

Mitigation Strategies:

• Robust Clinical Design: InnovaPharm has engaged with regulatory agencies and key opinion leaders to design its Phase III trials to maximize the probability of success.
• Diversified Indications: Progression into CDI and parasitic infections diversifies the therapeutic pipeline and potential future revenue streams.
• Strong IP Portfolio: Extensive patent protection provides a significant barrier against early generic competition.
• Strategic Partnerships: InnovaPharm is exploring potential partnerships for co-development or commercialization to share risk and accelerate market access.
• Pre-Commercial Planning: The company is proactively engaging with payers and healthcare providers to understand market access requirements and develop a comprehensive market entry strategy.

Key Takeaways

Metromidol presents a compelling investment opportunity within the anti-infective space, specifically targeting complicated intra-abdominal infections. Its development is anchored by strong intellectual property, a clear unmet need in the target indication, and a novel formulation designed for improved clinical performance. The drug's path to market is supported by ongoing Phase III trials, with a projected launch in mid-2025. Key risks include clinical trial outcomes and regulatory approval, which are mitigated by InnovaPharm's strategic planning and robust scientific foundation. Financial projections indicate significant revenue potential, assuming successful execution of its development and commercialization strategy.

Frequently Asked Questions

1. What is the expected duration of Metromidol's patent protection? Metromidol is projected to have patent protection extending beyond 2038 through its composition of matter and formulation patents, with regulatory exclusivities further extending market protection.

2. Are there any specific patient populations that would particularly benefit from Metromidol? Patients with a history of adverse events to standard metronidazole, elderly patients, or those with impaired renal or hepatic function may experience improved tolerability and efficacy with Metromidol due to its potentially optimized pharmacokinetic profile.

3. What is InnovaPharm Therapeutics' financial standing and funding status? InnovaPharm Therapeutics is a venture-backed company. Its financial standing is strong, with recent funding rounds successfully completing its preclinical and early clinical development. Further funding for late-stage development and commercialization is anticipated.

4. How does Metromidol's proposed pricing compare to existing treatments for cIAI? Metromidol is expected to be priced at a premium compared to generic metronidazole but will be competitive with other novel broad-spectrum antibiotics and combination therapies used in severe cIAI.

5. What are the regulatory pathways InnovaPharm is pursuing for Metromidol? InnovaPharm is pursuing standard regulatory pathways with the U.S. FDA and the European Medicines Agency (EMA), aiming for marketing authorization based on its Phase III clinical trial data.

Citations

[1] InnovaPharm Therapeutics. (2023). Corporate Investor Presentation. [Internal Company Document]. [2] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ [3] World Health Organization. (2020). Global action plan on antimicrobial resistance 2020-2030. [4] Market Research Report: Intra-Abdominal Infections Treatment Market (2022). Global Industry Analysis. [5] U.S. Patent and Trademark Office. (n.d.). Patent Search Database. Retrieved from https://www.uspto.gov/ [6] European Patent Office. (n.d.). Espacenet Patent Search. Retrieved from https://worldwide.espacenet.com/